Next-Generation Sequencing (NGS) in Hematologic Diagnostics
DOI:
https://doi.org/10.54393/pjhs.v5i05.1799Abstract
Next-Generation Sequencing (NGS) has played a vital role in eld of medical diagnostics by providing insights into the genetic
causes of various disorders. NGS enables the study of multiple genes linked to hematologic diseases simultaneously and is
especially helpful in the diagnosis of complicated diseases such as lymphomas, leukemias and myelodysplastic syndromes
[1]. NGS helps classify subtypes by detecting particular genetic changes, which is important for implementing the best
treatment plans.
NGS integration into hematologic diagnostics improves patient care by using high-resolution data and increasing diagnosis
accuracy. This is especially crucial for conditions where the clinical symptoms are similar. NGS-based genetic pro ling aids
in the prediction of patient outcomes and the course of disease, enabling more informed clinical decisions. Targeted therapy
development is made possible by NGS, which also minimizes side effects and maximizes therapeutic e cacy. Despite its
potential, the adoption of NGS faces several challenges including cost and accessibility, technical expertise and regulatory
and ethical considerations.
These di culties do, however, also provide opportunities: a broader use of NGS might greatly enhance diagnostic capacities
and raise the standard of healthcare provided worldwide. International research projects that concentrate on the genetic
components of hematologic illnesses can advance medical understanding worldwide and lead to novel therapeutic
approaches. Global rates of morbidity and death can be decreased by better managing hematologic illnesses by early and
precise diagnosis made possible by NGS.
Globally, next-generation sequencing has great potential to improve hematopoietic diagnosis and patient care. Unlocking
this technology's full potential will require addressing its cost, accessibility, and technical expertise limitations. Integrating
NGS into routine diagnostics could revolutionize the treatment of hematologic illnesses and improve patient outcomes and
prospects globally as the world's healthcare infrastructure develops
References
Thol F and Platzbecker U. Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS? Blood Advances. 2019 Nov; 3(21): 3449-53. doi: 10.1182/bloodadvances.2018022434. DOI: https://doi.org/10.1182/bloodadvances.2018022434
Tan DS, Tan DS, Tan IB, Yan B, Choo SP, Chng WJ et al. Recommendations to improve the clinical adoption of NGS‐based cancer diagnostics in Singapore. Asia‐Pacific Journal of Clinical Oncology. 2020 Aug; 16(4): 222-31. doi: 10.1111/ajco.13339 DOI: https://doi.org/10.1111/ajco.13339
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments